MLYSMineralys Therapeutics, Inc.

HealthcareUSD
$31.13
Latest close: back above its 200-day averageSep 8, 2026what changed →

The financials

Mineralys Therapeutics, Inc. by the numbers

Mineralys Therapeutics, Inc. income statement, Q2 2026 against the same quarter a year earlier
Income statementQ2 2026Q2 2025Change
Operating income−$246M−$47Mn/a
Net income−$241M−$43Mn/a
Diluted EPS−$2.85−$0.66n/a

Biotechnology

Ranks #26 of 143 by Smart Score

Compare peers
NRIX0.00%
Nurix Therapeutics, Inc.
PHVS+7.3%
Pharvaris N.V.
BHVN-6.1%
Biohaven Ltd.
SLBT-8.7%
SL Science Holding Limited
MRVI-1.6%
Maravai LifeSciences Holdings, Inc.
AUPH+0.03%
Aurinia Pharmaceuticals Inc.